{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:57:38Z","timestamp":1792155458698,"version":"4.4.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ajog.2019.08.043","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T01:55:21Z","timestamp":1567043721000},"page":"103-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy"],"prefix":"10.1016","volume":"222","author":[{"given":"Katie K.","family":"Crean-Tate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S.","family":"Faubion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly J.","family":"Pederson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Vencill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"Batur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2019.08.043_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-017-4305-6","article-title":"Sexual health needs and educational intervention preferences for women with cancer","volume":"165","author":"Stabile","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2019.08.043_bib2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11764-016-0585-9","article-title":"Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors","volume":"11","author":"Carter","year":"2017","journal-title":"J\u00a0Cancer Surviv"},{"key":"10.1016\/j.ajog.2019.08.043_bib3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/08870446.2013.879136","article-title":"Prevalence and correlates of sexual morbidity in long-term breast cancer survivors","volume":"29","author":"Raggio","year":"2014","journal-title":"Psychol Health"},{"key":"10.1016\/j.ajog.2019.08.043_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3580-2","article-title":"Self-reported sexual health: Breast cancer survivors compared to women from the general population\u2500an observational study","volume":"17","author":"Oberguggenberger","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/13697137.2014.946279","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society","volume":"17","author":"Portman","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2019.08.043_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/COC.0b013e318248d89d","article-title":"Sexual dysfunction in female cancer survivors","volume":"37","author":"DeSimone","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/GME.0000000000000926","article-title":"Missing documentation in breast cancer survivors: genitourinary syndrome of menopause","volume":"24","author":"Cook","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1019953027596","article-title":"Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy","volume":"75","author":"Broeckel","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2019.08.043_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","article-title":"Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer","volume":"20","author":"Baumgart","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2019.08.043_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1749-6632.2010.05680.x","article-title":"Menopause and sexuality: key issues in premature menopause and beyond","volume":"1205","author":"Graziottin","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ajog.2019.08.043_bib12","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.fertnstert.2013.08.018","article-title":"Sexual dysfunction in women with cancer","volume":"100","author":"Falk","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2019.08.043_bib13","doi-asserted-by":"crossref","DOI":"10.3109\/13697137.2015.1124259","article-title":"Treating vulvovaginal atrophy\/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?","volume":"19","author":"Edwards","year":"2016","journal-title":"Climacteric J Int Menopause Soc"},{"key":"10.1016\/j.ajog.2019.08.043_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1592\/phco.21.5.464.34486","article-title":"Urogenital atrophy: prevention and treatment","volume":"21","author":"Willhite","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ajog.2019.08.043_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0378-5122(95)00955-8","article-title":"Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women","volume":"23","author":"Bygdeman","year":"1996","journal-title":"Maturitas"},{"key":"10.1016\/j.ajog.2019.08.043_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0015-0282(16)56474-7","article-title":"Comparative study: Replens versus local estrogen in menopausal women","volume":"61","author":"Nachtigall","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2019.08.043_bib17","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A\u00a0practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial","volume":"33","author":"Goetsch","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/GME.0000000000000839","article-title":"Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes","volume":"24","author":"Sokol","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/GME.0000000000000672","article-title":"Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and\/or hormonal therapy for breast cancer: a retrospective study","volume":"23","author":"Pagano","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/GME.0000000000001053","article-title":"Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study","volume":"25","author":"Pagano","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00404-016-4118-6","article-title":"Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors","volume":"294","author":"Pieralli","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2019.08.043_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/GME.0000000000001293","article-title":"Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy","volume":"26","author":"Gordon","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib23","first-page":"1","article-title":"Sexual function after cancer: paying the price of survivorship","author":"Bober","year":"2019","journal-title":"Climacteric J Int Menopause Soc"},{"key":"10.1016\/j.ajog.2019.08.043_bib24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women\u02bcs Sexual Health","volume":"25","author":"Faubion","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib25","first-page":"CD001500","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2019.08.043_bib26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.ajog.2019.08.043_bib27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2010.483297","article-title":"Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets","volume":"13","author":"Eugster-Hausmann","year":"2010","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2019.08.043_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00042192-200205000-00006","article-title":"Treatment of urogenital atrophy with low-dose estradiol: preliminary results","volume":"9","author":"Santen","year":"2002","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/AOG.0b013e3181f386bb","article-title":"Endometrial safety of ultra-low-dose estradiol vaginal tablets","volume":"116","author":"Simon","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2019.08.043_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2019.08.043_bib32","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/01.AOG.0000241091.86268.6e","article-title":"Breast cancer risk in postmenopausal women using estrogen-only therapy","volume":"108","author":"Lyytinen","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2019.08.043_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women\u2019s Health Initiative Observational Study","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/GME.0000000000001284","article-title":"Vaginal estrogen use and chronic disease risk in the Nurses\u2019 Health Study","volume":"26","author":"Bhupathiraju","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib35","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.ejca.2005.07.015","article-title":"Vaginal oestrogen therapy after breast cancer: is it safe?","volume":"41","author":"Ponzone","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O\u2019Meara","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2019.08.043_bib37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case\u2013control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2019.08.043_bib38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/13697137.2013.806471","article-title":"Estrogen therapy in gynecological cancer survivors","volume":"16","author":"Guidozzi","year":"2013","journal-title":"Climacteric J Int Menopause Soc"},{"key":"10.1016\/j.ajog.2019.08.043_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.maturitas.2016.07.018","article-title":"Menopausal hormone therapy in cancer survivors: a narrative review of the literature","volume":"92","author":"Kuhle","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.ajog.2019.08.043_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jsbmb.2005.02.018","article-title":"Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina","volume":"96","author":"Berger","year":"2005","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ajog.2019.08.043_bib41","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1097\/GME.0000000000001238","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause","volume":"25","author":"Labrie","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/hmbci-2015-0044","article-title":"Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study","volume":"25","author":"Bouchard","year":"2016","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1016\/j.ajog.2019.08.043_bib43","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib44","first-page":"1335","article-title":"Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jsbmb.2013.08.002","article-title":"Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens","volume":"138","author":"Labrie","year":"2013","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ajog.2019.08.043_bib46","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/GME.0000000000000470","article-title":"Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women","volume":"22","author":"Portman","year":"2015","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1471-0528.1998.tb10056.x","article-title":"An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina","volume":"105","author":"Hodgins","year":"1998","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2019.08.043_bib48","first-page":"1262","article-title":"Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial","volume":"11","author":"Fernandes","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ajog.2019.08.043_bib49","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ajog.2019.08.043_bib50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/sm2.22","article-title":"Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy","volume":"2","author":"Dahir","year":"2014","journal-title":"Sex Med"},{"key":"10.1016\/j.ajog.2019.08.043_bib51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream versus estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2019.08.043_bib53","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of the North American Menopause Society","volume":"24","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/13697137.2010.522875","article-title":"Recommendations for the management of postmenopausal vaginal atrophy","volume":"13","author":"Sturdee","year":"2010","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2019.08.043_bib55","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/AOG.0000000000001351","article-title":"ACOG committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer","volume":"127","author":"Farrell","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2019.08.043_bib56","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1258\/136218005775544273","article-title":"Is there a role for hormone replacement therapy after breast cancer?","volume":"11","author":"Kwan","year":"2005","journal-title":"J\u00a0Br Menopause Soc"},{"key":"10.1016\/j.ajog.2019.08.043_bib58","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2019.08.043_bib59","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/GRF.0b013e3182083cbb","article-title":"Hormone replacement after breast cancer: is it safe?","volume":"54","author":"Liotta","year":"2011","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ajog.2019.08.043_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2019.08.043_bib61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib62","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy vs placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study","volume":"24","author":"Barakat","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib63","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","article-title":"Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis","volume":"50","author":"Shim","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib64","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ygyno.2018.03.008","article-title":"Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: a multicenter review","volume":"149","author":"Stewart","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib65","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/aogs.12720","article-title":"Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary","volume":"94","author":"van Meurs","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajog.2019.08.043_bib66","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2014.03.573","article-title":"Hormone therapy in ovarian granulosa cell tumors: a systematic review","volume":"134","author":"van Meurs","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib67","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2005.11.010","article-title":"Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature","volume":"101","author":"Pink","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib68","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib69","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/IGC.0b013e3181e9d0ba","article-title":"Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study","volume":"20","author":"Garg","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib70","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ygyno.2017.06.013","article-title":"Management of menopausal symptoms in women with gynecologic cancers","volume":"146","author":"Del Carmen","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib71","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib72","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib74","article-title":"Hormone replacement therapy in cancer survivors\u2500review of the literature","author":"Deli","year":"2019","journal-title":"Pathol Oncol Res POR. January"},{"key":"10.1016\/j.ajog.2019.08.043_bib75","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","article-title":"Hormonal replacement therapy in patients after cervical cancer treatment","volume":"26","author":"Ploch","year":"1987","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2019.08.043_bib76","unstructured":"National Cancer Institute. Diethylstilbestrol (DES) and cancer. Available at: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/hormones\/des-fact-sheet. 2011. Accessed July 28,\u00a02019."},{"key":"10.1016\/j.ajog.2019.08.043_bib77","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/GME.0000000000000624","article-title":"Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex\u00a0vivo","volume":"23","author":"Eigeliene","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2019.08.043_bib78","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"issue":"5 Suppl","key":"10.1016\/j.ajog.2019.08.043_bib79","doi-asserted-by":"crossref","first-page":"685","DOI":"10.6004\/jnccn.2016.0193","article-title":"Sexual function in cancer survivors: updates to the NCCN guidelines for survivorship","volume":"14","author":"Melisko","year":"2016","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.ajog.2019.08.043_bib80","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/1097-0142(19890101)63:1<204::AID-CNCR2820630133>3.0.CO;2-U","article-title":"Sexual dysfunction and treatment for early stage cervical cancer","volume":"63","author":"Schover","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2019.08.043_bib81","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2004.07.728","article-title":"Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients","volume":"61","author":"Schroder","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ajog.2019.08.043_bib82","first-page":"238","article-title":"Impact of a multidisciplinary vulvodynia program on sexual functioning and dyspareunia","volume":"12","author":"Brotto","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ajog.2019.08.043_bib83","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/sm2.17","article-title":"Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women","volume":"1","author":"Goldstein","year":"2013","journal-title":"Sex Med"},{"key":"10.1016\/j.ajog.2019.08.043_bib84","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.esxm.2018.04.003","article-title":"Biopsychosocial management of female sexual dysfunction: a pilot study of patient perceptions from 2 multi-disciplinary clinics","volume":"6","author":"Rullo","year":"2018","journal-title":"Sex Med"},{"key":"10.1016\/j.ajog.2019.08.043_bib85","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ajog.2016.07.045","article-title":"Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management","volume":"215","author":"Gandhi","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2019.08.043_bib86","first-page":"1827","article-title":"Sex therapy and combined (sex and medical) therapy","volume":"8","author":"Althof","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ajog.2019.08.043_bib87","first-page":"615","article-title":"Women\u2019s sexual pain disorders","volume":"7","author":"van Lankveld","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ajog.2019.08.043_bib88","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.mayocp.2011.09.004","article-title":"Recognition and management of nonrelaxing pelvic floor dysfunction","volume":"87","author":"Faubion","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ajog.2019.08.043_bib89","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/01.ogx.0000162246.06900.9f","article-title":"Musculoskeletal causes of chronic pelvic pain: a systematic review of existing therapies: part II","volume":"60","author":"Tu","year":"2005","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.ajog.2019.08.043_bib90","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00192-003-1071-2","article-title":"The effect of pelvic floor training on sexual function of treated patients","volume":"14","author":"Beji","year":"2003","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.ajog.2019.08.043_bib91","first-page":"4","article-title":"Reviews: pelvic floor involvement in male and female sexual dysfunction and the role of pelvic floor rehabilitation in treatment: a literature review","volume":"4","author":"Rosenbaum","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ajog.2019.08.043_bib93","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.mayocp.2017.08.019","article-title":"Genitourinary syndrome of menopause: management strategies for the clinician","volume":"92","author":"Faubion","year":"2017","journal-title":"Mayo Clin Proc"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937819310579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937819310579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:26:23Z","timestamp":1757589983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937819310579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0002937819310579"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2019.08.043","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2019.08.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}